醋酸艾司利卡西平预防卒中后癫痫:2a期随机对照试验
这项2a期双盲随机安慰剂对照试验纳入125例高卒中后癫痫风险的急性缺血性卒中或脑出血患者,比较醋酸艾司利卡西平800mg/日与安慰剂。
要点
- 醋酸艾司利卡西平800mg/日未能显著降低6个月内首次无诱因发作、死亡或停药的复合终点。
- 治疗中出现的不良事件两组频率相似(82% vs 82%),低钠血症在艾司利卡西平组更常见(8% vs 2%)。
- 试验把握度不足,置信区间宽,但证实抗癫痫发生研究可行,为设计更大样本试验提供依据。
核心结论
- 醋酸艾司利卡西平800mg/日与安慰剂相比,未显著改善6个月内首次无诱因发作、死亡或停药的复合终点。
- 试验因招募缓慢和COVID-19疫情而把握度不足,置信区间宽,需更大样本研究验证。
研究设计与样本
- 探索性、概念验证、2a期、双盲、随机、安慰剂对照试验,在奥地利、德国、意大利、以色列、葡萄牙、西班牙、瑞典和英国的19所大学医院开展。
- 纳入年龄≥18岁、急性缺血性卒中或急性脑出血后、SeLECT评分≥5或CAVE评分≥2的高风险患者,随机化计划在卒中已知时间或最后已知良好时间96小时内(修改后延长至120小时)。
- 129例筛查,125例随机分配(醋酸艾司利卡西平62例,安慰剂63例),口服800mg/日或安慰剂30天,随访17个月。
- 所有接受至少一剂研究药物的患者纳入安全性和有效性分析。
主要发现
- 治疗中出现的不良事件两组频率相似(醋酸艾司利卡西平组50/61(82%)vs 安慰剂组51/62(82%))。
- 最常见治疗中出现的不良事件为低钠血症(醋酸艾司利卡西平组5/61(8%)vs 安慰剂组1/62(2%))和头晕(3/61(5%)vs 0)。
- 严重治疗中出现的不良事件在醋酸艾司利卡西平组12例(20%),安慰剂组13例(21%)。
- 醋酸艾司利卡西平组发生3例严重相关治疗中出现的不良事件(结性心律失常、肝衰竭、低钠血症各1例),安慰剂组无。
关键数值与推荐
- 主要终点:随机化后6个月内首次无诱因发作、死亡或任何原因停药的患者比例。
- 高风险定义:SeLECT评分≥5或CAVE评分≥2。
- 给药方案:醋酸艾司利卡西平800mg/日或安慰剂,口服30天。
临床怎么用
- 目前证据不支持对高卒中后癫痫风险的卒中患者常规使用醋酸艾司利卡西平进行一级预防。
- 临床使用醋酸艾司利卡西平时需监测低钠血症和头晕等不良事件。
- 抗癫痫发生试验设计需考虑足够的样本量和招募策略,以临床相关终点评估疗效。
局限性
- 试验因招募缓慢和COVID-19疫情而把握度不足,置信区间宽。
- 探索性、概念验证设计,样本量小(125例),结果需进一步验证。
- 主要终点为复合终点,包括死亡和停药,可能稀释对癫痫发作预防效果的评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Eslicarbazepine acetate is an antiseizure medication that has shown potential antiepileptogenic effects in preclinical models of epilepsy. We aimed to investigate whether eslicarbazepine acetate could prevent or reduce the incidence of unprovoked seizures after acute ischaemic stroke or acute intracerebral haemorrhage. METHODS: Study BIA-2093-213 was an exploratory, proof-of-concept, phase 2a, double-blind, randomised, placebo-controlled trial conducted in adults (aged ≥18 years) after an acute ischaemic stroke or acute intracerebral haemorrhage, who were considered at high risk of developing unprovoked seizures based on a severity of stroke, large artery atherosclerosis, early seizure, cortical involvement, and territory of the middle cerebral artery (SeLECT) score of 5 or greater or a cortical involvement of intracerebral haemorrhage, age, volume, and early seizure after intracerebral haemorrhage (CAVE) score of 2 or greater. Patients were recruited from 19 university hospitals across Austria, Germany, Italy, Israel, Portugal, Spain, Sweden, and the UK, and eligible for inclusion if randomisation was planned within 96 h since the known time of stroke, or last time seen well (prolonged to 120 h to allow detection of acute seizures within 5 days post-stroke following a protocol modification implemented early in recruitment). Participants were randomly assigned (1:1) to receive eslicarbazepine acetate 800 mg/day or placebo, administered orally, for 30 days and followed up for 17 additional months. All patients who received one dose of study drug were included in safety and efficacy analyses. The primary endpoint was the proportion of patients who had a first unprovoked seizure, died, or discontinued (for any reason) within the first 6 months after randomisation. This trial is registered on the EudraCT database (EudraCT 2018-002747-29). FINDINGS: Between May 29, 2019, and Feb 28, 2022, 129 patients were screened and 125 were randomly assigned (62 to eslicarbazepine acetate and 63 to placebo). The between-group difference for the primary endpoint (17 [28%] of 61 with eslicarbazepine acetate vs 23 [37%] of 62 with placebo) was not significant (odds ratio 0·66 [95% CI 0·31-1·40]; p=0·37). Treatment-emergent adverse events were reported with similar frequency in both eslicarbazepine acetate and placebo groups (50 [82%] of 61 vs 51 [82%] of 62). The most common treatment-emergent adverse events were hyponatraemia (five [8%] of 61 in the eslicarbazepine acetate group vs one [2%] of 62 in the placebo group), dizziness (three [5%] vs none). Serious treatment-emergent adverse events were reported in 12 (20%) patients in the eslicarbazepine acetate group and 13 (21%) in the placebo group. Three serious related treatment-emergent adverse events occurred in the eslicarbazepine acetate group (none in the placebo group): nodal arrhythmia, hepatic failure, and hyponatraemia (one patient each). Five patients died after randomisation (all in the eslicarbazepine acetate group), but deaths were deemed unrelated or unlikely to be related to the study drug. INTERPRETATION: The proportion of patients who had a first unprovoked seizure, died, or discontinued at 6 months did not differ significantly between the eslicarbazepine acetate and placebo groups. However, the trial was underpowered owing to slow recruitment and the COVID-19 pandemic, producing wide confidence intervals. The findings indicate that antiepileptogenesis studies are feasible, and guide the design of adequately powered trials with clinically meaningful endpoints. FUNDING: BIAL.
引用
- Koepp MJ, Trinka E, Mah YH, et al. Safety and efficacy of eslicarbazepine acetate for seizure prevention in patients with stroke at high risk of developing post-stroke epilepsy: a proof-of-concept, phase 2a, randomised, double-blind, placebo-controlled antiepileptogenesis trial. Lancet Neurol. 2026. PMID: 41722592. doi:10.1016/S1474-4422(25)00491-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。